Proactive Investors - Run By Investors For Investors

Akers Biosciences Inc now in "every place where it’s important to be"

Raymond Akers, founder and executive chairman of Akers Biosciences Inc (NASDAQ:AKER, LON:AKR), says “this is gonna be a great year” after a “blazing start” to 2016.
The diagnostic test maker has been granted a US patent for the technology at the heart of a test that detects an allergy to the blood thinning drug Heparin.
The patent was just the tip of the iceberg as the group expands its reach. “We now have distribution in 33 countries around the world," says Akers who added the US$2.5mln order it received from China was a “taste of things to come.”

Meet Anglo Asian Mining Plc, Landore Resources Ltd., Stratex International plc and Chaarat Gold Holdings Ltd at our event, London, 03 November 2016. Register here »
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future Akers Biosciences, Inc. articles
View full AKR profile

Akers Biosciences, Inc. Timeline

August 11 2016

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.